Cancer vaccine - sigma-tau

Drug Profile

Cancer vaccine - sigma-tau

Latest Information Update: 29 Sep 2010

Price : $50

At a glance

  • Originator sigma-tau SpA
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 05 Mar 2007 Phase-I clinical trials in Solid tumours in Italy (Injection)
  • 07 Nov 2006 Preclinical trials in Cancer in Italy (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top